2 Unstoppable Dividend Stocks to Buy Right Now for Less Than $1,000
AI Sentiment
Positive
7/10
as of 03-09-2026 1:28pm EST
Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. On a 2025 sales basis, following the spinoff, BD Medical Essentials represented 34% of revenue, the Interventional segment 28%, Connected Care 25%, and Biopharma 13%. International revenue accounts for 43% of the company's business.
| Founded: | 1897 | Country: | United States |
| Employees: | N/A | City: | FRANKLIN LAKES |
| Market Cap: | 51.5B | IPO Year: | 1994 |
| Target Price: | $189.60 | AVG Volume (30 days): | 2.7M |
| Analyst Decision: | Buy | Number of Analysts: | 11 |
| Dividend Yield: | Dividend Payout Frequency: | semi-annual | |
| EPS: | 1.34 | EPS Growth: | -0.68 |
| 52 Week Low/High: | $162.46 - $231.82 | Next Earning Date: | 05-07-2026 |
| Revenue: | $21,840,000,000 | Revenue Growth: | 8.24% |
| Revenue Growth (this year): | -11.04% | Revenue Growth (next year): | 2.53% |
| P/E Ratio: | 124.92 | Index: | |
| Free Cash Flow: | 3.9B | FCF Growth: | -10.39% |
EVP, Chief Revenue Officer
Avg Cost/Share
$181.84
Shares
75
Total Value
$13,638.00
Owned After
21,308
SEC Form 4
Director
Avg Cost/Share
$182.61
Shares
953
Total Value
$174,027.33
Owned After
36,763
SEC Form 4
EVP, CRO & Pres. Life Sciences
Avg Cost/Share
$202.73
Shares
75
Total Value
$15,204.75
Owned After
21,308
SEC Form 4
EVP & Pres Med.Essntl&BioPharm
Avg Cost/Share
$207.77
Shares
1,610
Total Value
$334,005.40
Owned After
13,105
EVP, CRO & Pres. Life Sciences
Avg Cost/Share
$196.08
Shares
74
Total Value
$14,509.92
Owned After
21,308
SEC Form 4
EVP & Pres Med.Essntl&BioPharm
Avg Cost/Share
$196.03
Shares
629
Total Value
$123,302.87
Owned After
13,105
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Feld Michael | BDX | EVP, Chief Revenue Officer | Feb 26, 2026 | Sell | $181.84 | 75 | $13,638.00 | 21,308 | |
| SCOTT BERTRAM L | BDX | Director | Feb 18, 2026 | Sell | $182.61 | 953 | $174,027.33 | 36,763 | |
| Feld Michael | BDX | EVP, CRO & Pres. Life Sciences | Jan 26, 2026 | Sell | $202.73 | 75 | $15,204.75 | 21,308 | |
| Garrison Michael David | BDX | EVP & Pres Med.Essntl&BioPharm | Jan 15, 2026 | Sell | $207.77 | 1,610 | $334,005.40 | 13,105 | |
| Feld Michael | BDX | EVP, CRO & Pres. Life Sciences | Dec 26, 2025 | Sell | $196.08 | 74 | $14,509.92 | 21,308 | |
| Garrison Michael David | BDX | EVP & Pres Med.Essntl&BioPharm | Dec 17, 2025 | Sell | $196.03 | 629 | $123,302.87 | 13,105 |
SEC 8-K filings with transcript text
Feb 9, 2026 · 100% conf.
1D
-1.40%
$204.48
5D
-2.29%
$202.64
20D
-0.88%
$205.56
bdx-202602090000010795false00000107952026-02-092026-02-090000010795us-gaap:CommonStockMemberexch:XNYS2026-02-092026-02-090000010795bdx:Notes1.900dueDecember152026Memberexch:XNYS2026-02-092026-02-090000010795bdx:Notes1.208dueJune42026Memberexch:XNYS2026-02-092026-02-090000010795bdx:Notes1213DueFebruary122036Memberexch:XNYS2026-02-092026-02-090000010795bdx:Notes3.519DueFebruary82031Memberexch:XNYS2026-02-092026-02-090000010795bdx:Notes3.828DueJune72032Memberexch:XNYS2026-02-092026-02-09
Date of Report (Date of earliest event reported) February 9, 2026
(Exact Name of Registrant as Specified in Its Charter)
New Jersey
(State or Other Jurisdiction of Incorporation)
001-4802 22-0760120 (Commission File Number) (IRS Employer Identification No.)
1 Becton Drive, Franklin Lakes,New Jersey 07417-1880 (Address of Principal Executive Offices) (Zip Code)
(201) 847-6800
(Registrant’s Telephone Number, Including Area Code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K Filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each ClassTrading SymbolName of each exchange on which registered
Common stock, par value $1.00BDXNew York Stock Exchange 1.900% Notes due December 15, 2026BDX26New York Stock Exchange 1.208% Notes due June 4, 2026BDX/26ANew York Stock Exchange 1.213% Notes due February 12, 2036BDX/36New York Stock Exchange 3.519% Notes due February 8, 2031BDX31New York Stock Exchange 3.828% Notes due June 7, 2032BDX32ANew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On February 9, 2026, Becton, Dickinson and Company (“BD”) issued a press release announcing its financial results for its first fiscal quarter ending December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this report.
The press release furnished as Exhibit 99.1 contains certain financial measures that differ from those presented in accordance with U.S. generally accepted accounting principles (“non-GAAP measures”). Details regarding these non-GAAP measures and adjustments can be found in the schedules included in the press release furnished as Exhibit 99.1.
Exhibit 99.1 Press release dated February 9, 2026, which is furnished pursuant to Item 2.02.
Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
(Registrant)
By:/s/ Stephanie M. Kelly Stephanie M. Kelly Chief Securities and Governance Counsel, Corporate Secretary
Date: February 9, 2026
Nov 6, 2025
bdx-202511060000010795false00000107952025-11-062025-11-060000010795us-gaap:CommonStockMemberexch:XNYS2025-11-062025-11-060000010795bdx:Notes1.900dueDecember152026Memberexch:XNYS2025-11-062025-11-060000010795bdx:Notes1.208dueJune42026Memberexch:XNYS2025-11-062025-11-060000010795bdx:Notes1213DueFebruary122036Memberexch:XNYS2025-11-062025-11-060000010795bdx:Notes3.519DueFebruary82031Memberexch:XNYS2025-11-062025-11-060000010795bdx:Notes3.828DueJune72032Memberexch:XNYS2025-11-062025-11-06
Date of Report (Date of earliest event reported) November 6, 2025
(Exact Name of Registrant as Specified in Its Charter)
New Jersey
(State or Other Jurisdiction of Incorporation)
001-4802 22-0760120 (Commission File Number) (IRS Employer Identification No.)
1 Becton Drive, Franklin Lakes,New Jersey 07417-1880 (Address of Principal Executive Offices) (Zip Code)
(201) 847-6800
(Registrant’s Telephone Number, Including Area Code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K Filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each ClassTrading SymbolName of each exchange on which registered
Common stock, par value $1.00BDXNew York Stock Exchange 1.900% Notes due December 15, 2026BDX26New York Stock Exchange 1.208% Notes due June 4, 2026BDX/26ANew York Stock Exchange 1.213% Notes due February 12, 2036BDX/36New York Stock Exchange 3.519% Notes due February 8, 2031BDX31New York Stock Exchange 3.828% Notes due June 7, 2032BDX32ANew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On November 6, 2025, Becton, Dickinson and Company (“BD”) issued a press release announcing its financial results for its fourth fiscal quarter ending September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this report.
The press release furnished as Exhibit 99.1 contains certain financial measures that differ from those presented in accordance with U.S. generally accepted accounting principles (“non-GAAP measures”). Details regarding these non-GAAP measures and adjustments can be found in the schedules included in the press release furnished as Exhibit 99.1.
Exhibit 99.1 Press release dated November 6, 2025, which is furnished pursuant to Item 2.02.
Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
(Registrant)
By:/s/ Stephanie M. Kelly Stephanie M. Kelly Chief Securities and Governance Counsel, Corporate Secretary
Date: November 6, 2025
Oct 15, 2025
bdx-202510090000010795false00000107952025-10-092025-10-090000010795us-gaap:CommonStockMemberexch:XNYS2025-10-092025-10-090000010795bdx:Notes1.900dueDecember152026Memberexch:XNYS2025-10-092025-10-090000010795bdx:Notes1.208dueJune42026Memberexch:XNYS2025-10-092025-10-090000010795bdx:Notes1213DueFebruary122036Memberexch:XNYS2025-10-092025-10-090000010795bdx:Notes3.519DueFebruary82031Memberexch:XNYS2025-10-092025-10-090000010795bdx:Notes3.828DueJune72032Memberexch:XNYS2025-10-092025-10-09
Date of Report (Date of earliest event reported) October 9, 2025
(Exact Name of Registrant as Specified in Its Charter)
New Jersey
(State or Other Jurisdiction of Incorporation)
001-4802 22-0760120 (Commission File Number) (IRS Employer Identification No.)
1 Becton Drive, Franklin Lakes,New Jersey 07417-1880 (Address of Principal Executive Offices) (Zip Code)
(201) 847-6800
(Registrant’s Telephone Number, Including Area Code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K Filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each ClassTrading SymbolName of each exchange on which registered
Common stock, par value $1.00BDXNew York Stock Exchange 1.900% Notes due December 15, 2026BDX26New York Stock Exchange 1.208% Notes due June 4, 2026BDX/26ANew York Stock Exchange 1.213% Notes due February 12, 2036BDX/36New York Stock Exchange 3.519% Notes due February 8, 2031BDX31New York Stock Exchange 3.828% Notes due June 7, 2032BDX32ANew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On October 15, 2025, Becton, Dickinson and Company (the “Company”) issued a press release announcing its preliminary unaudited revenue for its fourth quarter and full fiscal year ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this report.
The press release furnished as Exhibit 99.1 contains certain financial measures that differ from those presented in accordance with U.S. generally accepted accounting principles (“non-GAAP measures”). Details regarding these non-GAAP measures and adjustments can be found in the schedules included in the press release furnished as Exhibit 99.1.
The information in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information in this Item 2.02 and Exhibit 99.1 shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
ITEM 5.02 DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS.
On October 9, 2025, Christopher J. DelOrefice informed Becton, Dickinson and Company (the “Company” or “BD”) of his intention to resign from his position as the Company’s Executive Vice President and Chief Financial Officer effective December 5, 2025 to pursue a new professional opportunity. Mr. DelOrefice will remain in his current role with the Company until his departure. Mr. DelOrefice’s departure is not the result of any disagreement with the Company on any matter relating to its financial statements, internal control over financial reporting, operations, policies or practices.
In connection with Mr. DelOrefice’s departure from the position of Chief Financial Officer, Vitor Roque, Senior Vice President of Finance, Business Units and Corporate Financial Planning & Analysis, has been appointed by the Company’s Board of D
BDX Breaking Stock News: Dive into BDX Ticker-Specific Updates for Smart Investing
AI Sentiment
Positive
7/10
AI Sentiment
Highly Positive
8/10
AI Sentiment
Positive
6/10
AI Sentiment
Positive
7/10
AI Sentiment
Highly Positive
8/10
AI Sentiment
Highly Positive
9/10
AI Sentiment
Positive
7/10
See how BDX stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "BDX Becton Dickinson and Company - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.